Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2/3 Application of Botulinum Neurotoxin Type A in Salivary Glands as a Treatment of Chronic Drooling in Patients With Cerebral Palsy: A Controlled Clinical Trial.

NCT01489904 is registered in ClinicalTrials.gov with Hospital Vall d'Hebron as lead sponsor.

NCT NCT01489904
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01489904 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2/3 Application of Botulinum Neurotoxin Type A in Salivary Glands as a Treatment of Chronic Drooling in Patients With Cerebral Palsy: A Controlled Clinical Trial.
Lead sponsor
Hospital Vall d'Hebron
Phase
Phase 2/3
Overall status
Unknown status
Start date
November 30, 2011
Completion date
November 30, 2012
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cerebral palsy, sialorrhea